Papers

Gestational impaired glucose tolerance does not increase perinatal mortality in a developing country: cohort study

BMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7293.1025 (Published 28 April 2001) Cite this as: BMJ 2001;322:1025
  1. Shenaz Ramtoola, specialista (sramtoola{at}cwcom.net),
  2. Philip Home, professorb,
  3. Hassen Damry, specialista,
  4. Anwar Husnoo, specialista,
  5. Stephen Ah-Kion, specialista
  1. a Dr A G Jeetoo Hospital, Port Louis, Mauritius
  2. b Human Diabetes and Metabolism Research Centre, University of Newcastle upon Tyne NE2 4HH
  1. Correspondence to: S Ramtoola
  • Accepted 20 November 2000

The high prevalence of diabetes and impaired glucose tolerance in women of childbearing age in Mauritius provides an opportunity to assess prospectively the risks of adverse outcome in pregnancy of these conditions, whether the conditions are known to be present at conception or diagnosed during pregnancy.1 The findings are likely to have consequences for healthcare planning in developing countries.

Outcome of pregnancy in Mauritius, 1993-6, according to diagnostic category of glucose intolerance. Values are number (percentage) unless otherwise indicated

View this table:

Participants, methods, and results

The study hospital (catchment population 250 000; 4500 deliveries a year) accounts for 22% of deliveries of babies in Mauritius, hospital deliveries being 80% of all deliveries on the island.1 Cases were registered in 1993–6 at a joint obstetric and medical service for diabetes, and were also found by monitoring admissions to the obstetric wards, and by monitoring all requests for obstetric oral glucose tolerance tests. Data were collected from the mother and from hospital and national records. Diabetes and impaired glucose tolerance were diagnosed using the 1985 WHO criteria.2 Outcomes were assessed as miscarriage (<28 weeks), stillbirth, live birth, or neonatal death (<1 week). Neonatal data were obtained from neonatal records, and background information was obtained from national statistics and routinely collected hospital obstetric data. Standard statistical tests were used for analysis of categorical and continuous data.

A total of 294 glucose intolerant pregnancies were registered in 270 women with diabetes or impaired glucose tolerance (mean age 31; SD 6 years). Of these, 110 cases were of pregestational onset and the remainder were diagnosed during pregnancy (86 diabetes, 98 impaired glucose tolerance); nine were lost to follow up and 18 miscarried.

Outcome in the 267 pregnancies resulting in live birth or stillbirth is shown in the table. Perinatal mortality was 124/1000 for women with pregestational diabetes and 116/1000 for women with gestational diabetes, giving relative risks well above the rate in the background population (26/1000). There was no excess perinatal mortality in women with gestational impaired glucose tolerance (22/1000). The excess perinatal mortality in women with pregestational diabetes comprised a similar excess of stillbirths and early neonatal mortality; in gestational diabetes it was related particularly to an excess of stillbirths (81/1000). All but one of the cases of perinatal mortality in gestational diabetes occurred in 43 women who had fasting hyperglycaemia ≥7.8 mmol/l at presentation.

Mean birth weight was significantly higher in babies born to women with gestational diabetes and impaired glucose tolerance than in the background population but not in babies born to women with pregestational diabetes (table). The incidence of macrosomia was highest in the gestational diabetes group and was also significantly increased in the pregestational diabetes group. It was not significantly increased in the group with gestational impaired glucose tolerance, despite this group having the highest gestational age at delivery. Four infants of mothers with pregestational or gestational diabetes weighed ≥4500 g (2%; relative risk 9.2 (3.0 to 29.0)) but none weighed ≥4500 g in the group with gestational impaired glucose tolerance. Rates of caesarean section were significantly above background in all the glucose intolerant groups (table). Both hypoglycaemia and hyperbilirubinaemia were significantly more common in infants of women with pregestational and gestational diabetes than in those of women with gestational impaired glucose tolerance (table).

Comment

In Mauritius women diagnosed as frankly diabetic during pregnancy carry the same risks as women with pregestational diabetes, but pregnancies with gestational impaired glucose tolerance have an outcome identical to that of the background population across several measures. This is consistent with reports from Belfast and Bangkok. 3 4 The 1999 WHO Consultation reiterated that the term “gestational diabetes” should encompass both gestational impaired glucose tolerance and diabetes, and that women with impaired glucose tolerance should be managed as women with frank diabetes.5 Worldwide, most cases found on screening in pregnancy are of impaired glucose tolerance rather than diabetes. 3 4 Our data do not support using limited resources in developing countries to identify women with impaired glucose tolerance and to manage them in line with WHO recommendations.

Acknowledgments

Contributors: SR initiated and coordinated the study, analysed and interpreted the data, and wrote the original paper that was submitted. SR and PH discussed core ideas, interpretation of data, and statistical analysis. PH edited the original paper and the final version. HD and AH helped coordinate the obstetric and neonatal aspects of the study and collect obstetric and neonatal data. AH devised and introduced a standardised neonatal observation protocol for infants of diabetic mothers. SA-K participated in the day to day running of the study, including case ascertainment and data collection. SR and PH are the guarantors for the study.

Footnotes

  • Funding No external funding; logistical support came from Ministry of Health of Mauritius.

  • Competing interests None declared.

  • Embedded Image This article is part of the BMJ's randomised controlled trial of open peer review. Documentation relating to the editorial decision making process is available on the BMJ's website

References

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
View Abstract